ImmunityBio to Present Prelim Phase 2 Data of 68% Durable Disease Control at ASCO

 

• Chemotherapy free regimen (with NK and T cell activation via Anktiva) in patients across multiple tumor types who failed checkpoint inhibitor therapy

• 140 patients accrued to date in this basket trial of checkpoint failures in lung cancer, melanoma, urothelial, head & neck, gastric and cervical cancer

• Out of 140 patients, 121 patients evaluable to date with 68% (82 out of 121) demonstrating durable disease control following Anktiva (IL-15 superagonist) plus checkpoint therapy after checkpoint failure

• Adverse events (AE) rates (12% grade 3 or above) of the chemo-free combination were better than historical standard of care alternative of combination chemotherapy

• Promising data forms the basis for the actively recruiting randomized Phase 3 clinical trials of Anktiva combination therapy in lung cancer patients (NCT03520686)

https://finance.yahoo.com/news/immunitybio-present-preliminary-phase-2-130000680.html